stockrowKymera Therapeutics, Inc. (KYMR) vs Protagonist Therapeutics, Inc. (PTGX)
- Kymera Therapeutics, Inc. KYMR 128.13 +1.18%
- Protagonist Therapeutics, Inc. PTGX 140.29 −3.15%
Kymera Therapeutics, Inc. and Protagonist Therapeutics, Inc. are both Biotechnology companies. Kymera Therapeutics, Inc. is the larger, with a market value of $10.8B against $9.4B — 1.2× the size. Kymera Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Protagonist Therapeutics, Inc. trades at 115×. Kymera Therapeutics, Inc. grew revenue faster over the last twelve months: 134.8% against 34.8%. Protagonist Therapeutics, Inc. has the higher net margin (29.4% vs 0.00%) and the higher return on invested capital (61.8% vs −39.3%). Across the 17 metrics below, Protagonist Therapeutics, Inc. leads on 13 and Kymera Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | KYMR | PTGX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 69.20% |
| Operating margin | 0.00% | 20.69% | 0.00% |
| Net margin | 0.00% | 29.40% | 0.00% |
| Free cash flow margin | 0.00% | 46.31% | 0.00% |
| Return on equity | (27.29%) | 10.98% | (53.10%) |
| Return on assets | (24.36%) | 10.34% | (46.06%) |
| Return on invested capital | (39.30%) | 61.84% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack